An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects with Advanced Solid Tumors or with B Cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with Diffuse Large B Cell Lymphoma
Disease Types
Lymphoma, Solid Tumors
Available at
Bethesda, Brandywine, Clinton, Columbia, Frederick, Rockville, Silver Spring, Wheaton
Contact
Linda Iovanni
MOHRSCH@usoncology.com